Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma
Top Cited Papers
- 24 November 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (47) , 19946-19951
- https://doi.org/10.1073/pnas.0907511106
Abstract
A key element for the development of suitable anti-cancer drugs is the identification of cancer-specific enzymatic activities that can be therapeutically targeted. Mucosa-associated lymphoid tissue transformation protein 1 (MALT1) is a proto-oncogene that contributes to tumorigenesis in diffuse large B-cell lymphoma (DLBCL) of the activated B-cell (ABC) subtype, the least curable subtype of DLBCL. Recent data suggest that MALT1 has proteolytic activity, but it is unknown whether this activity is relevant for tumor growth. Here we report that MALT1 is constitutively active in DLBCL lines of the ABC but not the GCB subtype. Inhibition of the MALT1 proteolytic activity led to reduced expression of growth factors and apoptosis inhibitors, and specifically affected the growth and survival of ABC DLBCL lines. These results demonstrate a key role for the proteolytic activity of MALT1 in DLBCL of the ABC subtype, and provide a rationale for the development of pharmacological inhibitors of MALT1 in DLBCL therapy.Keywords
This publication has 37 references indexed in Scilit:
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaBlood, 2009
- Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-κB and MAPK activation to selectively control cytokine productionBlood, 2008
- Multifunctional roles for MALT1 in T-cell activationNature Reviews Immunology, 2008
- β-Secretase as a Therapeutic Target for Alzheimer's DiseaseNeurotherapeutics, 2008
- Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphomaBlood, 2008
- Towards Triple Vasopeptidase Inhibitors for the Treatment of Cardiovascular DiseasesJournal of Cardiovascular Pharmacology, 2007
- Proteasome inhibitors: antitumor effects and beyondLeukemia, 2006
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006
- Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphomaLeukemia, 2004
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002